Industry News
Biotechnology Industry News
As deal-making rebounds in a…
As deal-making rebounds in a volatile year, Waterhouse Brands urges biotech firms to prioritize storytelling, credibility and long-term strategy.
After its cannabidiol gel…
After its cannabidiol gel candidate failed a phase 3 trial in fragile X syndrome, Harmony Biosciences has now paused development of the asset in a different genetic disease.
The spread of misinformation…
The spread of misinformation remains a major public health and reputational challenge.
Executives from Parexel spotlight…
Executives from Parexel spotlight AI integration, data-driven trial design and workforce transformation.
Pfizer may have launched a…
Pfizer may have launched a multifront legal battle to prevent Metsera from heading to Novo Nordisk, but, behind the scenes, the U.S. pharma has shown some willingness to rework its own deal.
PhaseV’s transparent AI platform…
PhaseV’s transparent AI platform helps sponsors reduce trial failures and accelerate drug development through smarter design and real-world data integration.
Merck & Co. began Tuesday with…
Merck & Co. began Tuesday with back-to-back deals, revealing separate agreements to pay $150 million upfront for full control of an early-phase asset and pocket $700 million to support an expansive pivotal oncology push.
The precision oncology biotech is…
The precision oncology biotech is pausing work on SMARCA2 degraders and selling a licensing option to Incyte Therapeutics.
Nuvation Bio has backed off from…
Nuvation Bio has backed off from its plans to directly compare its brain cancer drug to Servier's Voranigo, instead opting to focus on patients who aren’t covered by the approved competitor.
Korean biosimilar specialist…
Korean biosimilar specialist Celltrion has penned a deal worth more than $740 million biobucks for two preclinical autoimmune assets from U.S. biotech Kaigene.
A new West Coast biotech has…
A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed with $82 million
Foresight Diagnostics shared…
Foresight Diagnostics shared insights into the evolving role of minimal residual disease (MRD) testing in precision oncology.
AI-powered platform streamlines…
AI-powered platform streamlines regulatory processes, boosts collaboration and accelerates drug development timelines.
Biotech leader outlines how early…
Biotech leader outlines how early strategic alignment, cross-functional collaboration and AI-driven insights are reshaping commercialization success.
AI-powered Derisq platform offers…
AI-powered Derisq platform offers biotech and investment firms a faster, more accurate way to assess clinical trial risk and improve capital efficiency
Tempero Bio has hit the brakes on…
Tempero Bio has hit the brakes on a phase 2-stage alcohol use disorder program while the biotech considers its options, according to the program’s partner.
FDA is said to be making a U-turn…
FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the treatment being hailed as a game changer.
Roche may have been exploring ways…
Roche may have been exploring ways to shuttle drugs to the brain for well over a decade, but that's not stopping the pharma from handing $55 million to Manifold Bio for a fresh route through
TScan Therapeutics is laying off…
TScan Therapeutics is laying off 30% of its workforce as the T-cell receptor therapy biotech abandons a phase 1 solid tumor trial and focuses on patients with blood cancers.
Neurocrine Biosciences has penned…
Neurocrine Biosciences has penned a deal with China’s TransThera Sciences potentially worth more than $880 million in biobucks for inhibitors aimed at a red-hot inflammation target.